---
title: "Tofflon and others established a biotechnology company with a registered capital of 100 million yuan"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/257463799.md"
description: "According to the Qichacha APP, recently, Yantai Bosai Biotechnology Co., Ltd. was established with a registered capital of 100 million yuan. Its business scope includes drug production, drug wholesale, drug retail, and drug contract manufacturing, among others. Qichacha's equity penetration shows that the company is jointly held by Tofflon and others"
datetime: "2025-09-16T03:33:40.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/257463799.md)
  - [en](https://longbridge.com/en/news/257463799.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/257463799.md)
generator: "portal-rs"
---

# Tofflon and others established a biotechnology company with a registered capital of 100 million yuan

According to the Qichacha APP, recently, Yantai Bosai Biotechnology Co., Ltd. was established with a registered capital of 100 million yuan. Its business scope includes drug production, drug wholesale, drug retail, and entrusted drug production, among others. Qichacha's equity penetration shows that the company is jointly held by Tofflon and others

### Related Stocks

- [300171.CN](https://longbridge.com/en/quote/300171.CN.md)

## Related News & Research

- [US SEC investigating Situational Awareness trades that led to July meltdown, source says](https://longbridge.com/en/news/296829164.md)
- [UPDATE -- Helium Evolution Closes $25 Million Private Placement](https://longbridge.com/en/news/296948264.md)
- [LB Group : Revenue up 8.15% but net profit down 39.08% amid cost pressures and major share buyback](https://longbridge.com/en/news/297034690.md)
- [Beyond Frames shareholders to vote on 6,000,000-share issue at SEK 1.7 each](https://longbridge.com/en/news/296866537.md)
- [CONX takes controlling stake in MobileX in strategic investment deal](https://longbridge.com/en/news/296831211.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**